Kairos Pharma, Ltd. announced that its Board authorized a one-for-seven reverse stock split of its common stock, effective September 1, 2026. The company filed a Certificate of Amendment with the Delaware Secretary of State on August 21, 2026, to implement the split, which was previously approved by shareholders at the June 29, 2026 annual meeting. Every seven pre-split shares will combine into one post-split share, with fractional shares rounded up to the nearest whole share. The transaction aims to increase the per-share trading price and maintain compliance with NYSE American listing requirements. Kairos Pharma is a clinical-stage biopharmaceutical company focused on oncology therapeutics.

Kairos Pharma, Ltd. entered into an Investigator/Institution Initiated Research (IIR) Agreement with Bayer HealthCare Pharmaceuticals Inc. to evaluate the combination of its lead antibody ENV-105 (carotuximab) with Bayer's XOFIGO (radium-223 dichloride) for metastatic castration-resistant prostate cancer. Under the agreement, Bayer will provide radium for the study, while Kairos Pharma is responsible for the financing and management of the study and must provide Bayer with final analysis and interpretation within 6 months of study completion. Kairos Pharma is a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance.

Kairos Pharma, Ltd. issued a press release on July 15, 2026, reporting interim safety data from its ongoing Phase 1 clinical trial for ENV-105 (Carotuximab) in combination with osimertinib for patients with advanced EGFR-mutated non-small cell lung cancer. Kairos Pharma, Ltd. is a pharmaceutical company focused on developing clinical-stage drug candidates.

At its June 29, 2026 annual meeting, Kairos Pharma Ltd. stockholders approved an amendment to the certificate of incorporation to allow a reverse stock split with a ratio between 1:3 and 1:250, to be determined by the Board of Directors. Stockholders also approved increasing the 2023 Equity Incentive Plan by 5,000,000 shares of common stock and adding an evergreen provision for a 5% annual increase in available shares for ten years. Additionally, the company elected four directors, ratified Weinberg & Company, P.A. as independent auditors, and approved executive compensation on an advisory basis. The company operates in the pharmaceutical industry and develops medical treatments.